Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boro...

Are there any disclosed risks or uncertainties (e.g., trial setbacks, regulatory challenges) that could impact future performance? How does AN2’s boron‑chemistry platform and Chagas program compare to competitors developing treatments for the same indications? What upcoming catalysts (e.g., data readouts, regulatory filings, conference presentations) could drive the stock in the next weeks?
Symbol: ANTX
Earnings
25 days ago
Read more businesswire

Leonardo DRS Successfully Completes First Open-Water Demonstration of its Counter-UAS Maritime Mission Equipment Package for Small Uncrewed Surface Vessels

ARLINGTON, Va.--(BUSINESS WIRE)--Leonardo DRS, Inc. (NASDAQ: DRS) announced today that is has successfully completed its first series of open-water demonstrations of its advanced maritime Mission E...

How might this news affect the stock’s short‑term price action and trading volume? Will the demonstration influence analyst sentiment or trigger any upgrades/downgrades from rating agencies? What are the risks or challenges associated with scaling the land‑based C‑UAS technology to maritime platforms?
Symbol: DRS
Defense
25 days ago
Read more businesswire

Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogen...

How does Lineage Cell Therapeutics' valuation compare to other all‑ogeneic cell therapy companies after this release? What is the expected market size for the neurological and ophthalmic indications the company is targeting? Did the company address any potential risks or challenges that could impact the upcoming trial readouts?
Symbol: LCTX
Earnings
25 days ago
Read more businesswire

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026

What is the expected effect on the company’s valuation multiples (e.g., EV/Revenue, P/E) once the IND is filed and proof‑of‑concept is achieved? How might the upcoming Q3 earnings call and business updates influence short‑term trading volumes? Are there any risks or contingencies in the development plan that could delay the IND filing or proof‑of‑concept timeline?
Symbol: EDIT
Earnings
25 days ago
Read more globenewswire

RXST INVESTOR NOTICE: RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

SAN DIEGO, Aug. 12, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the RxSight class action lawsuit – captioned Makaveev v. RxSight, Inc., No. 25-cv-01596 (C.D. Cal.) – seeks ...

How does the legal exposure compare to RxSight’s competitors who have faced similar litigation? Will there be any insider trading activity or unusual volume surrounding the announcement that could signal market positioning? What precedent does this case set for similar ophthalmic device companies and could it affect industry valuations?
Symbol: RXST
Lawsuits
25 days ago
Read more prnewswire

Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease

- Cognition and FDA align on enriched population, study design, and endpoints -

How does the sentiment score of 70 reflect market perception, and could it shift after further trial updates? Will the alignment on endpoints influence the choice of biomarkers and impact trial costs? What is the expected market size for an approved Alzheimer’s disease treatment and how could Cognition capture share?
Symbol: CTOT
Clinical
25 days ago
Read more globenewswire

First Trust Announces Elections/Re-Elections of Trustees for ETFs and Other Open-End Funds

WHEATON, Ill.--(BUSINESS WIRE)--At special meetings of shareholders held on August 12, 2025 (collectively, the “Meetings”), shareholders of the open-end management investment companies (collectivel...

Will the appointment of these trustees impact the long‑term performance and risk metrics of the underlying funds? How does this board election compare to recent governance changes at competing ETF providers? Could this governance event impact regulatory compliance or tax considerations for investors in the OEFs/ETFs?
Symbol: FTI
Governance
25 days ago
Read more businesswire

Spectral Medical and Vantive Announce Topline Results from Spectral’s Tigris Trial Evaluating PMX Hemoadsorption Therapy for Endotoxic Septic Shock

TORONTO, Ontario and DEERFIELD, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis an...

What are the next steps in the clinical development program—additional Phase 3 trials, expanded indications, or post‑marketing studies? How might the results impact the stock's valuation relative to peers in the theranostics and critical care space? Will the trial data trigger any milestone payments or earn‑out provisions in existing agreements?
Symbol: EDT
Clinical trials
25 days ago
Read more globenewswire